KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Twist Bioscience (TWST) Operating Expenses (2017 - 2026)

Twist Bioscience has reported Operating Expenses over the past 10 years, most recently at $156.6 million for Q1 2026.

  • Quarterly Operating Expenses rose 16.54% to $156.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $548.3 million through Mar 2026, changed 0.1% year-over-year, with the annual reading at $512.8 million for FY2025, 3.93% down from the prior year.
  • Operating Expenses was $156.6 million for Q1 2026 at Twist Bioscience, up from $136.6 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $170.4 million in Q2 2024 and troughed at $98.9 million in Q4 2022.
  • The 5-year median for Operating Expenses is $123.4 million (2024), against an average of $126.0 million.
  • Year-over-year, Operating Expenses skyrocketed 57.39% in 2022 and then fell 25.95% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $98.9 million in 2022, then grew by 19.83% to $118.5 million in 2023, then rose by 4.12% to $123.4 million in 2024, then increased by 10.73% to $136.6 million in 2025, then rose by 14.63% to $156.6 million in 2026.
  • Per Business Quant, the three most recent readings for TWST's Operating Expenses are $156.6 million (Q1 2026), $136.6 million (Q4 2025), and $128.9 million (Q3 2025).